Standalone revenue growth of 20-30% CAGR over 3-5 years
Management expects standalone business to grow at 20-30% annually, driven by order book conversion and new molecule commercialization.
ANURAS / guidance tracker
Keep management guidance in view.
Anupam Rasayan India · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
No major capex in near future; maintenance capex of ₹50-75 crore
All plants are commercialized; current capacity sufficient for near-term growth. Only maintenance and efficiency capex planned.
Bliss GVS Pharma capacity utilization to reach 60-70% in near to medium term
Management plans to increase Bliss's capacity utilization from 30% to 60-70%, leveraging Anupam's customer relationships and expertise.
Effective tax rate on standalone basis to be ~25% going forward
Management guided for a lower tax rate of around 25% on standalone operations.